Article
Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
International journal of cancer - 15 Aug 2013
Kim Areumnuri, Lee Jung-Eun, Lee Seung-Sook, Kim Cherin, Lee Sun-Joo, Jang Won-Suk, Park Sunhoo
Abstract excerpt
Colorectal cancer (CRC) with mutational activation of KRAS is observed frequently. In addition, PIK3CA mutations commonly coexist with KRAS mutations and lead to additive activation of the PI3K/MTOR signaling pathway. Here, we investigated how CRC cells that harbor KRAS and PIK3CA mutations affect sensitivity to inhibition of PI3K/MTOR with NVP-BEZ235 (BEZ235). We selected CRC patient samples and assessed their...
Topics
- Animals
- Antineoplastic Agents
- Blotting, Western
- Cell Line, Tumor
- Class I Phosphatidylinositol 3-Kinases
- Colorectal Neoplasms
- Female
- Flow Cytometry
- Genes, ras
- Humans
- Imidazoles
- Immunohistochemistry
- Mice